psalexa
logo

Alzheimer’s Disease Pipeline Analysis

Alzheimer’s Disease Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: March 2017
Report Code: LS10885
Available Format:
Pages: 254

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

This report includes the Alzheimer’s disease pipeline analysis as of 2017, to analyze the emerging therapies and their progress status in different phases of development. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to Alzheimer's disease.

Alzheimer's Disease Pipeline Analysis

  • By phase
    • Phase III
    • Phase II
    • Phase I
    • Pre-Clinical
    • Discovery
  • By route of administration
    • Oral
    • Intravenous
    • Subcutaneous
    • Parenteral
    • Intravenous/ Subcutaneous
    • Intranasal
    • Inhalation
    • Not Disclosed
  • By target
    • Amyloid beta (Aβ) protein
    • Tau protein
    • Beta secretase (BACE)
    • 5-hydroxytryptamine 6 (5HT6) receptor
    • Cholinesterase enzyme
    • Others
  • By company

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 4000
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 5000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 8000

Pre-Purchase Enquiry